Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Mansfield CA, Van Houtven G, Huber J. The efficiency of political mechanisms for siting nuisance facilities: are opponents more likely to participate than supporters? J Real Estate Financ Econ. 2001;22(2/3):141-62.